BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• FDA

  Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA for the Treatment of TK2 Deficiency

  Designation Based on Compelling Data from Initial Clinical Studies and High Unmet Need in Thymidine Kinase 2 Deficiency

  February 19, 2019

   · 

  2 min read
• Business

  DenseBreast-Info.org Hails Federal Law that Mandates that Mammography Reports Include Breast Density Information

  FDA to Develop Notification Standard to Ensure All Women Receive Appropriate Information about their Personal Breast Density

  February 19, 2019

   · 

  3 min read
• Policy

  ReWalk Announces 510k FDA Submission for ReStore™ Exo-Suit for Stroke Rehabilitation

  Innovation in robotic rehabilitation technology will provide the first-of-its-kind medical device to rehab clinics nationwide, to treat the millions of patients with lower limb disability due to stroke

  February 19, 2019

   · 

  8 min read
• Business

  Nobel Prize Winner Professor Aaron Ciechanover appointed senior member on the advisory committee of Panaxia Pharmaceutical

  Dr. Dadi Segal, CEO and founder of Panaxia: “The entrance of a world-renowned scientist places Panaxia Pharmaceutical as a leading contender in the industry, and acts as a vote of confidence in the company’s capabilities.”

  February 19, 2019

   · 

  2 min read
• Deals

  Incyte to Present at Upcoming Investor Conferences - February 19, 2019

  Incyte Corporation announced that it will present at the following investor conferences during the month of March:

  February 19, 2019

   · 

  1 min read
• Drug Development

  Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201

  Novus Therapeutics, Inc., a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, announced that it has dosed the first patients in a phase 2a trial of OP0201, the company’s lead product candidate being developed for otitis media.

  February 19, 2019

   · 

  5 min read
• Drug Development

  Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors

  Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics, announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors.

  February 19, 2019

   · 

  3 min read
• Business

  4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives

  4D Molecular Therapeutics, a world-leader in Therapeutic Vector Evolution for adeno-associated virus gene therapy vector discovery and product development, announced the appointments of Fred Kamal, PhD, as chief technical officer, and August Moretti as chief financial officer.

  February 19, 2019

   · 

  5 min read
• Drug Development

  Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

  Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, shared additional clinical results from the MoveDMD trial of edasalonexent.

  February 19, 2019

   · 

  7 min read
• Job Trends

  Mindfulness and Stress Reduction Linked to Solutions for Menopause According to Mary Jo Rapini M.Ed, LPC

  A recent Mayo Clinic study published in Climacteric: The Journal of the International Menopause Society indicates that practicing mindfulness may be one solution for women suffering from menopausal symptoms

  February 19, 2019

   · 

  1 min read